119 related articles for article (PubMed ID: 36650953)
1. Hypermethylation of HIC2 is a potential prognostic biomarker and tumor suppressor of glioma based on bioinformatics analysis and experiments.
Luo F; Liao Y; Cao E; Yang Y; Tang K; Zhou D; Zhou D; Cai H
CNS Neurosci Ther; 2023 Apr; 29(4):1154-1167. PubMed ID: 36650953
[TBL] [Abstract][Full Text] [Related]
2. The T-box transcription factor brachyury behaves as a tumor suppressor in gliomas.
Pinto F; Costa ÂM; Santos GC; Matsushita MM; Costa S; Silva VA; Miranda-Gonçalves V; Lopes CM; Clara CA; Becker AP; Neder L; Hajj GN; da Cunha IW; Jones C; Andrade RP; Reis RM
J Pathol; 2020 May; 251(1):87-99. PubMed ID: 32154590
[TBL] [Abstract][Full Text] [Related]
3. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
4. HIC2 is a novel dosage-dependent regulator of cardiac development located within the distal 22q11 deletion syndrome region.
Dykes IM; van Bueren KL; Ashmore RJ; Floss T; Wurst W; Szumska D; Bhattacharya S; Scambler PJ
Circ Res; 2014 Jun; 115(1):23-31. PubMed ID: 24748541
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
6. A Novel Tumor-Suppressor, CDH18, Inhibits Glioma Cell Invasiveness Via UQCRC2 and Correlates with the Prognosis of Glioma Patients.
Bai YH; Zhan YB; Yu B; Wang WW; Wang L; Zhou JQ; Chen RK; Zhang FJ; Zhao XW; Duan WC; Wang YM; Liu J; Bao JJ; Zhang ZY; Liu XZ
Cell Physiol Biochem; 2018; 48(4):1755-1770. PubMed ID: 30078018
[TBL] [Abstract][Full Text] [Related]
7. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
8. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑940 promotes cell proliferation and invasion of glioma by directly targeting Kruppel‑like factor 9.
Zhang D; Hao P; Jin L; Wang Y; Yan Z; Wu S
Mol Med Rep; 2019 Jan; 19(1):734-742. PubMed ID: 30431124
[TBL] [Abstract][Full Text] [Related]
10. Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma.
Maimaiti A; Wang X; Hao Y; Jiang L; Shi X; Pei Y; Feng Z; Kasimu M
J Mol Neurosci; 2021 Aug; 71(8):1622-1635. PubMed ID: 33713320
[TBL] [Abstract][Full Text] [Related]
11. Identification of FABP7 as a Potential Biomarker for Predicting Prognosis and Antiangiogenic Drug Efficacy of Glioma.
Hou L; Zhou H; Wang Y; Liu J; Zhang D; Li Y; Xue X
Dis Markers; 2022; 2022():2091791. PubMed ID: 35783014
[TBL] [Abstract][Full Text] [Related]
12. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
13. Adaptor Protein Complex 1 Sigma 3 Is Highly Expressed in Glioma and Could Enhance Its Progression.
Ye T; Cheng Y; Li C
Comput Math Methods Med; 2021; 2021():5086236. PubMed ID: 34367317
[TBL] [Abstract][Full Text] [Related]
14. miR‑143 acts as a novel Big mitogen‑activated protein kinase 1 suppressor and may inhibit invasion of glioma.
Chen WY; Lang ZQ; Ren C; Yang P; Zhang B
Oncol Rep; 2019 Sep; 42(3):1194-1204. PubMed ID: 31322249
[TBL] [Abstract][Full Text] [Related]
15. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
16. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
Gömöri E; Pál J; Kovács B; Dóczi T
Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
[TBL] [Abstract][Full Text] [Related]
17. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
[TBL] [Abstract][Full Text] [Related]
18. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
[TBL] [Abstract][Full Text] [Related]
19. Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma.
Shu C; Wang Q; Yan X; Wang J
J Mol Neurosci; 2018 Apr; 64(4):491-500. PubMed ID: 29502292
[TBL] [Abstract][Full Text] [Related]
20. MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients.
Saini M; Jha AN; Tangri R; Qudratullah M; Ali S
Hum Mol Genet; 2021 Jan; 29(21):3532-3545. PubMed ID: 33105486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
